COMMUNIQUÉS West-GlobeNewswire

Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
06/03/2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and [...]
Avalyn to Participate in Leerink Partners Global Biopharma Conference
06/03/2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary diseases, today [...]
Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
06/03/2024
AU ZH, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will be [...]
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
06/03/2024
NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]
Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024
06/03/2024
Presentation will take place during the “Cancer Vaccines: Ready for Prime Time?” session on April 7, from 3:00 - 5:00pm PT at the San Diego Convention Center FORT LAUDERDALE, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- [...]
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
06/03/2024
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it [...]
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024
06/03/2024
BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies [...]
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
06/03/2024
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare [...]
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
06/03/2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual [...]
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
06/03/2024
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations
06/03/2024
ANN ARBOR, Mich., March 06, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), announces today that it is preparing a second business investment application in [...]
Kamada Issues 2024 CEO Letter to Shareholders
06/03/2024
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for [...]
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
06/03/2024
Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250) Pre-clinical results demonstrate that palazestrant, as both [...]
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06/03/2024
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today [...]
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
06/03/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
06/03/2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA [...]
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
06/03/2024
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and [...]
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
06/03/2024
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced [...]

Pages